linjc16/ctgov huggingface dataset:
Treatment of Residual Myopic Refraction After 6 Months on Pseudophakic Patients Using Relex-Smile

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess visual and refractive outcomes after laser vision correction (LVC) - ReLex Smile to correct residual myopic refraction after 6 months of pseudophakic (IOL) implantation. Before SMILE YAG-Laser capsulotomy should be performed on all patients, regardless of posterior capsule ossification, in pseudophakic patients with residual refraction. When the YAG Laser is applied after the SMILE, there will be a diopter change.

Detailed Description
-----------------
The residual myopic refraction after 6 month on pseudophakic patients using Relex-Smile surgery using VisuMax Femtosecond Laser.The residual myopic refractive power is between -0.75D till -5.50D.The optical zone(lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively.After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5mm incision and marked with a sterile marker(Viscot-Medster)

Official Title
-----------------
Treatment of Residual Myopic Refraction After 6 Months on Pseudophakic Patients Using Relex-Smile

Conditions
-----------------
Pseudophakia, Myopia

Intervention / Treatment
-----------------
* Procedure: Relex-Smile surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: residual myopic refraction -0.75d till -5.50D complain visual acuity regarding residual myopic refraction Exclusion Criteria: active anterior segment pathologic features previous corneal or anterior segment surgery glaucoma history of ocular inflammation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: One group consisting of 40 eyes
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: ReLex Smile surgery<br>Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was between -0.75D till -5.50D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(Viscot-Medster). | Procedure: Relex-Smile surgery<br>* surgery using Relex-Smile<br>* Other names: Relex smile surgery;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase of visual acuity | Treatment of residual myopic refraction on Pseudophakic patients, was performed using ReLex Smile after 6 months. | 6 months |
The BabyGrow Longitudinal Study of Nutrition and Growth in Preterm Infants

Study Overview
=================
Brief Summary
-----------------
This is a longitudinal, observational study on nutrition, growth and body composition in preterm infants. Aims to determine the adequacy of actual nutrient intake during the preterm period by investigating associations between macronutrient supply, growth, and body composition at 34-weeks gestation, term equivalent and 2-month corrected gestational age.

Detailed Description
-----------------
Infants between 23 and 24 weeks gestation and with a birth weight of 500 to 1500 g are recruited to a longitudinal, observational study of nutrition, growth and body composition in Cork University Maternity Hospital, Ireland.

Official Title
-----------------
The BabyGrow Longitudinal Study of Nutrition and Growth in Preterm Infants

Conditions
-----------------
Premature Birth of Newborn, Malnutrition; Intrauterine or Fetal, Small-for-dates

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Babies with a birth weight ≤1.5kg and gestational age ≤34 weeks were considered eligible. Exclusion Criteria: presence of congenital abnormalities or conditions that interfere with growth or body composition (congenital diseases, chromosomal abnormalities, chronic lung disease, cardiac or gastrointestinal diseases).

Ages Eligible for Study
-----------------
Maximum Age: 34 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Actual nutrient intake vs recommended nutrient requirements in preterm infants | Comparison of intake with requirements during the preterm infant's hospital stay and up to 2 months corrected gestational age. | 19 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Longitudinal data on body composition in Irish preterm neonates | Evaluation of appropriateness of current feeding regimens for achievement of optimal growth & body composition outcomes | 19 months | 
| Longitudinal data on vitamin D intake and circulating 25(OH)D | To examine the relationship between vitamin D intake and serum 25-hydroxyvitamin D concentrations and biomarkers of calcium handling by analysis of sequential serum samples. | 19 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preterm birth, Parenteral and enteral nutrition, Body composition in preterm infants
Plaque Registration and Event Detection In Computed Tomography

Study Overview
=================
Brief Summary
-----------------
Disruption of an atherosclerotic plaque is responsible for at least two-thirds of acute coronary syndrome. Thus, identification of plaques vulnerable to rupture has become important. The natural history of individual plaques is unknown and needs to be established. Multidetector computed tomography (MDCT) angiography is a useful noninvasive imaging modality for assessing coronary plaque characteristics. Using MDCT, the researchers prospectively investigate the relationship between the characterization of coronary plaques and cardiovascular events in a large multicenter study.

Official Title
-----------------
Prospective Multicenter Study to Investigate the Relationship Between the Characteristics of Coronary Artery Plaques and Cardiovascular Events Using Multidetector Computed Tomography Coronary Angiography

Conditions
-----------------
Atherosclerosis, Cardiovascular Diseases, Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with known or suspected coronary artery disease. Exclusion Criteria: irregular heart beat, known allergy towards the contrast agent, renal dysfunction, uncontrolled heart failure, previous coronary bypass surgery, or pacemaker or ICD implantation, ST elevation MI or unstable hemodynamic condition, impossible breath-hold, OR end-stage cancer.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major cardiac events (Cardiac death and acute coronary syndrome) |  | 2 years after the CT-scan | 
| All-cause death |  | 2 years after the CT-scan | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All coronary events (Cardiac death, non-fatal MI, unstable angina requiring hospitalization, late coronary revascularizations) |  | 2 years after CT-scan | 
| All cardiovascular events (Death, acute coronary syndrome, heart failure, cerebral disease, peripheral artery disease, aortic disease, and renal failure) |  | 2 years after the CT-scan |
The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effectiveness of bacteria called Lactobacillus GG, a Probiotic, in preventing the growth of resistant bacteria in the digestive tract in patients on a ventilator.

Official Title
-----------------
The Use of the Probiotic, Lactobacillus Rhamnosus GG to Evaluate Colonization With Antimicrobial Resistant Bacteria in High Risk Patients

Conditions
-----------------
Infectious Disease of Digestive Tract

Intervention / Treatment
-----------------
* Dietary Supplement: Lactobacillus rhamnosus GG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults ≥ 18 years old Admission to the Medical ICU Expected to be on Mechanical Ventilation through an endotracheal tube for >48 hours Exclusion Criteria: Pregnancy Immunosuppression Prosthetic valve or vascular graft Cardiac trauma Pancreatitis History of rheumatic fever Endocarditis or congenital cardiac abnormality Gastroesophageal or intestinal injury or foregut surgery during the current admission Oropharyngeal mucosal injury Placement of a tracheostomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Probiotic<br>Patients randomized to probiotic therapy will receive 1 capsule containing 1010 cells of Lactobacillus rhamnosus GG on a twice-daily basis | Dietary Supplement: Lactobacillus rhamnosus GG<br>* 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis<br>* Other names: Culturelle;|
| No Intervention: Standard of Care<br>Patients in the control arm will receive standard care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Combination of Gastrointestinal Tract Colonization With Multi-drug Resistant Gram-negative Bacteria, C. Difficile and VRE | Colonization of the gastrointestinal tract with C. difficile, vancomycin-resistant enterococci, multidrug-resistant Acinetobacter baumannii, and multidrug- resistant Pseudomonas. Colonization occurs when the subject acquires the above organism while in the study. | Participants will be followed while Intubated, an expected average of 7 days. The outcome will be measured 3 days after enrollment and at the end of intubation, average time 7 days) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Probiotics
Clinical Evaluation of Ultrasonic Hydration Monitor for Infants

Study Overview
=================
Brief Summary
-----------------
Study will verify ability of infant Hydration Monitor (IHM) to assess changes of hydration status in newborns and infants by means of ultrasound velocity measurements through muscle tissues. Changes of tissue hydration will be followed during first days of life in newborns and in acute diarrhea in small children during re-hydration therapy. Weighting and clinical dehydration symptoms will be used as controls.

Official Title
-----------------
Study of Ultrasonic Hydration Monitor for Neonatology and Pediatric Children and Infants and/or Children up to Age 3 Years Old With Diarrhea

Conditions
-----------------
Diarrhea, Dehydration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newborns from 1 to 7 days old, Health infants from 1 month to 3 years old, Any ethnicity, Male or female, Infants with diarrhea, Acute gastroenteritis, Diarrhea and/or vomiting, Suspected dehydration Exclusion Criteria: Congenital heart disease, Renal failure, Chronic liver disease, Chronic lung disease, Inflammatory bowel disease, Immune deficiency, Severe malnutrition, Any external damage to skin of leg, Infants and Children whose parents refuse permission to be included

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the ability of IHM to measure changes of hydration status ni newborn and infants | Infants and small children diagnosed with diarrhea or presenting to the hopsital with diseases known to cause dehydration are eligible | 1 week to several months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dehydration, Hydration, Muscle composition, Diarrhea, Pediatrics, Neonatology, Ultrasound
Complementary Effect of Reflexology on Chemotherapy-Induced Nausea and Vomiting

Study Overview
=================
Brief Summary
-----------------
Reflexology treatment may influence the severity of chemotherapy-induced nausea and vomiting. This study aims to investigate the clinical effect of reflexology on chemotherapy-induced nausea and vomiting.

Conditions
-----------------
Reflexology

Intervention / Treatment
-----------------
* Other: Reflexology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chemotherapy patients Exclusion Criteria: Myocardial Infarction in previous 6 months Mechanical colonic obstruction
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Chemotherapy patients<br>Chemotherapy patients will receive reflexology treatment | Other: Reflexology<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Severity of Nausea | Nausea will be assessed both before after three weeks of reflexology treatment by Common Toxicity Criteria Adverse Events Tool | Three weeks | 
| Change in Severity of Vomiting | Vomiting will be assessed both before after three weeks of reflexology treatment by Common Toxicity Criteria Adverse Events Tool | Three weeks |
Clinical and Radiographic Evaluation of Different Thickness of Vacuum Formed Retainer (Essix Retainer) During Retention Phase After Orthodontic Treatment

Study Overview
=================
Brief Summary
-----------------
vacuum formed retainer act as bite raiser that increase vertical dimension which may affect Tempromandibular joint and aim of this study is to perform clinical and radiographic evaluation of different thickness of vacuum formed retainer (Essix retainer) during retention phase after orthodontic treatment

Official Title
-----------------
Clinical and Radiographic Evaluation of Different Thickness of Vacuum Formed Retainer (Essix Retainer) During Retention Phase After Orthodontic Treatment

Conditions
-----------------
Temporomandibular Joint Disorders After Using Essix Retainer

Intervention / Treatment
-----------------
* Device: Retainer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients finished fixed orthodontic treatment with no signs or symptoms of temporomandibular joint disorders patients indicated for removable retainer Exclusion Criteria: any systemic disease chronic medication uptake bad oral hygiene pathological conditions of temporomandibular joint

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group 1 (Wrapround retainer)<br> | Device: Retainer<br>* Orthodontic retainer<br>|
| Group 2 (Essix retainer 1mm)<br> | |
| Group 3 (Essix retainer 1.5 mm)<br> | |
| Group 3 (Essix retainer 2mm)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical effect of retainer on temporomandibular joint | Absence of pain, deviation and trismus | 9 months | 
| Radiographic effect of retainer on tempromandibular joint | Normal dissc position | 9 months |
Changes in Vitreous Temperature During Phacoemulsification

Study Overview
=================
Brief Summary
-----------------
Temperature in the vitreous cavity decreases during vitrectomy, and the same effect is seen during an uneventful phaco surgery. Significant changes occur between the baseline temperature and after every step of the surgery.

Detailed Description
-----------------
A 23-gauge thermometer probe inserted prior to the beginning of the cataract surgery to measure the vitreous temperature at different stages of the procedure (capsulorrhexis, hydrodissection, phacomulsification, irrigation/aspiration and intraocular lens (IOL) implantation). Room temperature also registered during every step. At the end of the surgery, oral temperature will be measured.

Official Title
-----------------
Changes in Vitreous Temperature During Phacoemulsification

Conditions
-----------------
Proliferative Diabetic Retinopathy

Intervention / Treatment
-----------------
* Device: Phacoemlsification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients from the Retina department that underwent phacoemulsification and vitrectomy Exclusion Criteria: Posterior capsule rupture
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Thermoprobe<br>Determination of vitreous temperature with a thermoprobe | Device: Phacoemlsification<br>* Transurgical measurement of temperature<br>* Other names: Thermoprobe;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vitreous temperature | Temperature of the vitreous is taken every five minutes from the start of a phacoemulsification. Also Temperature is take after every step of the surgery (capsulorhexis, hydrodissection, phacoemulsification, irrigation/aspiration, IOL implantation). | Every five minutes during a phacoemulsification procedure, and at every step of the surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cataract, Phacoemulsification, Temperature, Vitreous
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

Study Overview
=================
Brief Summary
-----------------
Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.

Official Title
-----------------
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Other: Hyperoxia Exposure
* Other: Normoxia Exposure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy, type 2 diabetes BMI 18-40 kg/m2, non-pregnant, non-breastfeeding, non-nicotine users. Exclusion Criteria: cardiovascular disease including myocardial infarction, heart failure, coronary artery disease, stroke; renal or hepatic diseases; active cancer; autoimmune diseases; immunosuppressant therapy; excessive alcohol consumption (>14 drinks/week); current nicotine use; foot ulcers; diabetic neuropathy; medication directly influencing sympathetic nervous system activity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Interventional Model Description: After screening, participants will complete two study visits.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oral Glucose Tolerance Test<br>Subjects will consume a 75 g glucose drink within 1-min and monitored for 2 hours. | Other: Hyperoxia Exposure<br>* 2 hours of hyperoxia exposure during OGTT<br>Other: Normoxia Exposure<br>* 2 hours of normoxia exposure during OGTT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose change in response to OGTT |  | 2 hours post glucose ingestion | 
| Insulin change in response to OGTT |  | 2 hours post glucose ingestion |